By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Pharmacology. According to news originating from Jefferson, Arkansas, by NewsRx correspondents, research stated, "Until now the overlapping and diverse pharmacological protective mechanisms of different compounds in the treatment of cerebral ischemia, both on the signaling pathway and network levels have not been revealed. In order to find differential pathway networks from gene expression profiles of hippocampus of ischemic mice treated with baicalin (BA), ursodeoxycholic acid (UA) and jasminoidin (JA), a microarray comprising 16,463 genes, FDA Arraytrack software and Ingenuity Pathway Analysis, was employed."
Our news journalists obtained a quote from the research from Food and Drug Administration, "A total of 5, 8, 11, 9 networks and 6, 7, 40, 16 pathways were found in vehicle (vs sham), BA, UA and JA (vs vehicle), respectively. Only 4 and 7 overlapping pathways were shared between BA and UA, UA and JA, accounting for 9.3% and 14.3% of the total number of all pathways, respectively. BA, UA and JA all acted on Ca2+-dependent signaling cascades in diverse links. BA intervened in arachidonic acid metabolism. UA affected eicosanoid, cyclin-dependent kinase 5, nuclear factor-kappa B, and T-helper 1 cell cytokine production. It was found that JA might decrease oxidative damage via nuclear factor erythroid 2-related factor 2-mediated antioxidant response. Compared to vehicle, no overlapping pathways were found among three groups. However, the total of 60 (71.4%) overlapping functions could be approximately divided into diseases and disorders, molecular and cellular functions, physiological system development and function as categories with ratio of 1:1:1."
According to the news editors, the research concluded: "Analysis of network functions and known pathways may be two complementary paradigms for revealing potential pharmacological mechanisms based on the same phenotype variation."
For more information on this research see: Hierarchical Profiles of Signaling Pathways and Networks Reveal Two Complementary Pharmacological Mechanisms. CNS & Neurological Disorders-Drug Targets, 2013;12(6):882-893. CNS & Neurological Disorders-Drug Targets can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates (see also Pharmacology).
The news correspondents report that additional information may be obtained from Y.Y. Chen, Food & Drug Administration, Z Technical Corp, Jefferson, AR 72007, United States. Additional authors for this research include F.Y. Meng, H. Fang, Y.N. Yu, J. Liu, Z.W. Jing, A.P. Lv, Z. Wang and Y.Y. Wang.
Keywords for this news article include: Therapy, Arkansas, Jefferson, Pharmacology, United States, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC